Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

C1 inhibitor deficiency: hereditary and acquired forms.

A P Kaplan1

  • 1Department of Medicine, Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston 29425, USA. kaplana@musc.edu

Journal of Investigational Allergology & Clinical Immunology
|March 23, 2002
PubMed
Summary

C1 inhibitor deficiency, hereditary or acquired, causes swelling due to bradykinin release, not complement activation. Treatments include androgens, antifibrinolytics, or replacement therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Arerugi = [Allergy]·2023
Same author

Arerugi = [Allergy]·2023
Same author

An Atypical Case of Idiopathic Nonhistaminergic Angioedema With Anti-C1-INH Antibodies.

Journal of investigational allergology & clinical immunology·2022
Same author

Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria.

Journal of the European Academy of Dermatology and Venereology : JEADV·2017
Same author

Why a registry of Chronic Urticaria (CUR) is needed.

The World Allergy Organization journal·2017
Same author

Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.

Allergy·2016

Area of Science:

  • Immunology
  • Genetics
  • Biochemistry

Background:

  • C1 inhibitor (C1 INH) deficiency presents as hereditary or acquired conditions.
  • Hereditary forms include Type I (low normal C1 INH) and Type II (functional C1 INH defect).
  • Acquired forms involve C1 INH consumption (lymphoma, connective tissue disease) or autoimmune mechanisms.

Purpose of the Study:

  • To elucidate the mechanisms underlying C1 inhibitor deficiency.
  • To differentiate between hereditary and acquired types.
  • To clarify the pathophysiology of swelling and identify treatment strategies.

Main Methods:

  • Review of genetic and molecular mechanisms of C1 INH synthesis and function.
  • Analysis of clinical presentations and associations of acquired C1 INH deficiency.

Related Experiment Videos

  • Pathophysiological correlation between C1 INH absence, bradykinin, and swelling.

    • Main Results:

    • Hereditary C1 INH deficiency results from genetic defects affecting C1 INH levels or function.
    • Acquired C1 INH deficiency is linked to consumption or autoimmune processes.
    • Swelling is attributed to uncontrolled bradykinin release due to lack of C1 INH inhibition, independent of complement activation.

    Conclusions:

    • C1 inhibitor deficiency encompasses diverse hereditary and acquired etiologies.
    • Bradykinin pathway dysregulation, not complement, drives the characteristic swelling.
    • Therapeutic options include androgens, antifibrinolytics, and replacement therapy.